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Abstract
Background: To describe the epidemiology and trends of imported malaria in the Netherlands from 2000 through
2007.
Methods: Based on national surveillance data regarding all reported infections of imported malaria, diagnosed
2000 through 2007, incidence and trends of imported malaria in the Netherlands were estimated. Travellers
statistics were used to estimate incidence, and data on malaria chemoprophylaxis prescriptions were used to
estimate the number of unprotected travellers.
Results: Importation of malaria to the Netherlands is declining even as more travellers visit malaria-endemic
countries. On average, 82% were acquired in sub-Saharan Africa, and 75% were caused by Plasmodium falciparum.
The overall incidence in imported falciparum malaria fell from 21.5 to 6.6/10,000 of unprotected travellers. The
percentage of unprotected travellers rose from 47% to 52% of all travellers. The incidence of imported falciparum
infections is greatest from Middle and West Africa, and decreased from 121.3 to 36.5/10,000 travellers. The import
of malaria from this region by immigrants visiting friends and relatives (VFR) decreased from 138 infections in 2000,
to 69 infections in 2007.
Conclusion: The annual number of imported malaria shows a continuing declining trend, even with an increasing
number of travellers visiting malaria endemic countries. VFR import less malaria than previously, and contribute
largely to the declining incidence seen. The decline is not readily explained by increased use of chemoprophylaxis
and may reflect a reduced risk of infection due to decreasing local malaria transmission as observed in some
malaria endemic areas. Nevertheless, the increasing number of unprotected travellers remains worrisome.
Background
Malaria is the world’s most important parasitic disease
and is endemic in more than 105 countries. About 3.3
billion people, or half of the world’sp o p u l a t i o n ,a r ea t
risk of malaria. Every year there are about 250 million
malaria cases and nearly one million deaths [1,2], mostly
in malaria-endemic regions. An infection acquired in an
endemic region, but diagnosed in a non-endemic coun-
try, usually after development of clinical symptoms, is
defined as imported malaria [1,3,4]. Such diagnoses may
occur either in travellers who have recently toured or
visited endemic regions or in travellers from endemic
regions who are visiting a non-endemic country.
Travellers from non-endemic regions are generally
advised to use personal protective measures and malaria
chemoprophylaxis when visiting malaria-endemic
regions. Yet despite the availability of adequate chemo-
prophylactic drugs in the Netherlands and other non-
endemic countries, imported malaria continues to cause
considerable morbidity and mortality among returning
travellers. Immigrants from endemic countries and
returning to their country of origin to visit friends and
relatives (VFR) are a particular risk group among these
[5,6]. From the 1970s onward, the annual importation of
malaria to Europe showed a steady increase. In the late
1990s, these imported cases in Europe were estimated
to number at least 10,000 to 13,000 per year, excluding
many that are believed to be unreported [7-9].
The aim of this research is to present a comprehen-
sive overview of trends in imported malaria in the
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In addition, the annual incidence of Plasmodium
falciparum infections is estimated using travel
statistics regarding the annual number of travellers to
malaria-endemic regions, as well as data from Dutch
pharmacies regarding annual prescriptions for malaria
chemoprophylaxis.
Methods
Malaria infections
In the Netherlands, all laboratory-confirmed infections of
malaria are reported to the National Institute for Public
Health and the Environment (RIVM). Since such reports
became compulsory in 1932, the system of reporting has
changed over the years. In order to minimize underre-
porting of malaria infections in the Netherlands, the
reporting system was changed in 1999 from doctor-based
to laboratory-based reporting. Underreporting before
that time was estimated to be about 60% [10]. All infec-
tions reported between January 1, 2000, and December
31, 2007 were analysed, using the following surveillance
data: date of laboratory confirmation of the Plasmodium
species (results of conventional microscopy with subse-
quent specification of the Plasmodium species), patient
data (gender, date of birth, country of birth, and country
of mother’s birth), and travel information (most likely
country of infection, reason for travel). Infected persons
were classified as to ethnic origin based on the reported
country of their birth and/or their mother’sb i r t h .T h e y
were classified into four categories based on their reason
for travel; Western tourists visiting endemic countries;
Dutch expatriates living in endemic countries (including
military and airline personnel); visiting residents from
endemic countries (including new immigrants, asylum
seekers, refugees); and immigrants (or their descendants)
from endemic countries to the Netherland who visit
friends and relatives (VFR) in those countries. In this
report, these categories will be referred to as, tourists,
expatriates, visitors and VFR, respectively. In the period
2000-2003, data on some of these variables were missing.
In 2003, a new digital reporting system was introduced,
providing more complete information.
Traveller statistics
Only data on malaria-endemic countries, for which the
Malaria Working Group of Dutch the National Coordi-
nation Centre for Travellers’ Health Advice (LCR)
advises travellers to take malaria chemoprophylaxis were
used[11]. See additional file 1 for a list of all travel desti-
nations included. When no country-specific travel data
were available, regional data were used instead. Coun-
tries were grouped into continental regions and sub-
regions according to the composition of macro-geogra-
phical regions described by the United Nations Statistics
Division [12].
Malaria chemoprophylaxis prescriptions
Data on the number of annual prescriptions for malaria
chemoprophylaxis (atovaquone/proguanil, mefloquine,
and proguanil), collected from pharmacies in the Neth-
erlands by the Foundation for Pharmaceutical Statistics
(SFK) [13], were employed to estimate the annual num-
ber of travellers using the chemoprophylaxis. Chloro-
quine was not included because it is generally
prescribed in combination with proguanil, and not as a
single chemoprophylactic drug. Doxycycline was not
included, because it is not recommended as a first drug
of choice, and according to National Coordination Cen-
tre for Travellers’ Health Advice (LCR), only sporadi-
cally prescribed as a malaria chemoprophylactic drug. It
is mostly prescribed for other indications than malaria
prophylaxis.
Data analysis
The incidence of imported P. falciparum malaria in the
Netherlands was estimated using the annual number of
reported P. falciparum infections as numerator and the
number of travellers to malaria-endemic regions as
denominator. Imported infections in visiting residents
from malaria-endemic countries were excluded from this
part of the analysis, as visiting residents from malaria-
endemic countries are no part of the travellers statistics.
Incidence specific to a region or a sub-region was esti-
mated using the number of reported P. falciparum
infections from that region or sub-region as numerator
and the annual number of travellers to that region or
sub-region as denominator.
In addition, assuming that P. falciparum infection
mainly occurs in travellers not using chemoprophylaxis,
the incidence of imported P. falciparum malaria in unpro-
tected travellers from the Netherlands was calculated. The
annual number of unprotected travellers was estimated by
deducting the number of annual prescriptions for malaria
chemoprophylaxis from the total of travellers to malaria-
endemic regions., A region-specific incidence for “unpro-
tected” travellers only could not be calculated, because
data on prescriptions from Dutch pharmacies do not
include data on destination. Trends in infection probability
(incidence) were modelled via Poisson regression. Trends
in relative contribution of reason for travel were modelled
via multinomial logistic regression. All time trends were
fitted using restricted cubic splines, to allow for smoothly
varying trends over time [14]. Analyses were performed in
the R statistical package.
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Imported infections of malaria 2000-2007
From 2000 through 2007, a total of 2,847 persons were
diagnosed with malaria in the Netherlands. The annual
number of imported malaria infections fell from 535 in
2000 to 197 in 2007. Most infections (92% or 2,624)
occurred in adults; 5% occurred in children aged 6-15
years, and 3% in children five years or younger. The
median age of infection was 36 years, and 33% of
patients were female. Table 1 shows the annual number
of reported infections by Plasmodium species. As in
11% (322) of all confirmed infections the causative spe-
cies was not specified, mainly in the years 2000 through
2003, estimates were calculated. In the column ‘adjusted’
of Table 1, the unknown Plasmodium species were pro-
portionally distributed among the four species, based on
their respective annual contribution. Most recorded
infections (2,131 or 75%) were caused by P. falciparum.
The remainder was caused by Plasmodium vivax (15%),
Plasmodium ovale (7%), and Plasmodium malariae
(3%). A very small proportion of all infections (20 or
0.7%) was attributable to mixtures of species, most of
which involved P. falciparum. Despite a decrease in the
absolute number of infected patients, the relative distri-
bution of the causative species remains fairly stable over
the time period studied (p = 0.58).
Region of infection
In 88% (2,511) of the records, the most likely country of
infection was supplied. Table 2 shows the continental
region and sub-region where the infections were
acquired, by Plasmodium species. Most infections were
acquired in Africa, (2,068 or 82%), followed by Asia (298
or 12%) and Middle and South America (142 or 6%).
From 2000 through 2007, the annual number of
imported Plasmodium infections from Africa almost
halved, from 310 to 159 infections per year. Infections
from Middle and South America fell from 27 in 2000 to
seven in 2007. Imported infections from Asia varied,
ranging from 18 to 63 infections per year.
Infections acquired in Asia were for the greater part
(64%) caused by P. vivax, whereas those acquired in
Africa were for the greater part (80%) caused by P. falci-
parum. Almost all P. falciparum infections (1,658 or
94%) were acquired in Africa. Of these, 80% (1,337)
were acquired in the West African sub-region, with
most coming from Ghana (550) followed by Nigeria
(280) and the Gambia (126). Importation of P. falci-
parum from West Africa decreased from 182 infections
in 2000 to 124 infections in 2007. The decrease was
seen for all countries in this sub-region except Nigeria,
which showed an increase.
Reason for travel
Information regarding the reason of the travel was avail-
able for 82% (2,346) of cases.
Of these, 53% were adults and children who had
emigrated from malaria-endemic countries, settled in
the Netherlands, and were subsequently visiting friends
and relatives. Infections in these VFR declined from
210 in 2000 to 77 in 2007. Among Western tourist tra-
vellers (666 or 28%), infections declined from 122 to
53 over the study period. In expatriates (309 or 13%),
infections remained stable, ranging from 32 and 50 per
year.
In 119 cases (5%), the diagnosis of malaria was made
in visiting residents from malaria endemic countries,
mostly from the African region. The number of infec-
tions diagnosed in visiting residents increased from
three in 2000 to 24 in 2007. The relative contributions
for all four categories of patients to the probability of an
imported malaria infection were estimated. Figure 1
shows the fitted trends of the probability of infection for
all four categories of patients with 95% confidence inter-
vals. The probability of infection in VFR and Western
tourists show a declining trend, whereas the probability
Table 1 Reported infections of malaria in the Netherlands. 2000-2007 In the column ‘adjusted’ unknown Plasmodium
species were proportionally distributed among the four species based on their respective annual contribution
Species P. falciparum P. ovale P. vivax P. malariae Total Not specified
Year No. No. corrected (%) No. No. corrected (%) No. No. corrected (%) No. No. corrected (%)
2000 295 413 (77,2%) 28 39 (7,3%) 52 73 (13,6%) 7 11 (1,8%) 535 (153)
2001 313 390 (71,3%) 34 42 (7,7%) 78 97 (17,8%) 14 17 (3,2%) 547 (108)
2002 269 294 (74,3%) 29 32 (8,0%) 53 58 (14,6%) 11 12 (3,0%) 396 (34)
2003 244 255 (75,1%) 24 25 (7,4%) 49 51 (15,1%) 8 8 (2,5%) 340 (15)
2004 199 201 (68,6%) 25 25 (8,6%) 60 61 (20,7%) 6 6 (2,1%) 293 (3)
2005 232 235 (78,9%) 22 22 (7,5%) 33 33 (11,2%) 7 7 (2,4%) 298 (4)
2006 186 189 (78,5%) 14 14 (5,9%) 30 31 (12,7%) 7 7 (3.0%) 241 (4)
2007 151 152 (77,0%) 8 8 (4,1%) 33 33 (16,8%) 4 4 (2,0%) 197 (1)
Total 1,889 2,130 (74,8%) 184 208 (7,3%) 388 437 (15,4%) 64 72 (2,5%) 2,847 (322)
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Netherlands, 2000-2007
Region P. falciparum P. ovale P. vivax P. malariae Species unknown Total
Africa 1,658 (94%) 157 (94%) 78 (22%) 47 (78%) 128 (80%) 2,068 (82%)
Middle & West Africa
1 1413 110 23 39 89 1674
East & Southern Africa
2 245 47 55 8 39 394
America 43 (2%) 2 (1%) 79 (23%) 7 (12%) 11 (7%) 142 (6%)
Middle America
3 4 0 17 0 5 24
South America
4 39 2 62 7 6 118
Asia 71 (4%) 9 (5%) 192 (55%) 5 (8%) 21 (13%) 298 (12%)
South Asia
5 20 0 57 3 9 89
South East Asia
6 51 9 135 2 12 209
Oceania 2 (0.1%) 0 (0.0%) 0 (0.0%) 1 (2%) 0 (0.0%) 3 (0.1%)
Sub total 1,774 (100%) 169 (100%) 349 (100%) 60 (100%) 160 (100%) 2,511 (100%)
Region of infection unknown 115 15 39 4 162 336
Total 1,889 184 388 64 322 2,847
1Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Central African Republic, Chad, Côte d’Ivoire, Congo, the Democratic republic of Congo, Gabon, The
Gambia, Ghana, Equatorial Guinea, Guinea, Guinea-Bissau,, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Principe, Senegal, Sierra Leone, Togo.
2Botswana, Burundi, Djibouti, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Nauru, Namibia, Rwanda, South Africa, Somalia, Sudan, Swaziland, Tanzania,
Uganda, Zimbabwe.
3Anguilla (U.K.), Antigua and Barbuda, Aruba, the Bahamas, Barbados, Belize, Bermuda (U.K.), Cayman Islands (U.K.), Costa Rica, Cuba, Dominica, Dominican
Republic, El Salvador, Grenada, Guadeloupe, Guatemala, Haiti, Honduras, Jamaica, Martinique (France), Mexico, Montserrat (U.K.), Netherlands Antilles, Nicaragua,
Panama, Puerto Rico (U.S.), Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands (U.K.), Virgin
Islands, British, Virgin Islands, U.S.
4Argentina, Bolivia, Brazil, Chile, Colombia, Easter Island (Chile), Ecuador, Falkland Islands (U.K.), French Guiana (France), Guyana, Paraguay, Peru, South Sandwich
Islands, Suriname, Uruguay, Venezuela.
5Afghanistan, Bangladesh, Bhutan, India, Iraq, Iran, Maldives, Nepal, Oman, Pakistan, Sri Lanka.
6Brunei, Burma (Myanmar), Cambodia, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand, Timor-Leste (East Timor), Vietnam.
Figure 1 Fitted trends in probability of infection for the four categories of patients with imported malaria, the Netherlands, 2000-
2007. The probability of infection is shown with 95% confidence intervals.
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malaria endemic countries is increasing.
Ethnic origin
Information on the ethnic origin of the patients was
available in 75% (2,141) of the records. Of these
patients, almost half (1,042 or 49%) were persons of
Middle and West African origin, mainly from Ghana
(452) and Nigeria (221), of which 98% and 95% acquired
the infection in the country of origin, respectively. Of
these, 11% (115/1,042) were aged 16 years or younger.
The number of infections in persons of Middle and
West African origin declined from 150 in 2000 to 80 in
2007, and in persons of East and Southern African ori-
gin from 22 in 2000 to 10 in 2007. Approximately a
third (769 or 36%) of the infections were in persons of
D u t c he t h n i co r i g i n ,o fw h i c h5 %w e r ei nc h i l d r e na g e d
16 years or younger. The countries in which Dutch per-
sons most frequently acquired infection were Ghana
(102), Indonesia (78), or the Gambia (72). The number
of infections in persons of Dutch ethnic origin fluctu-
ated between 68 and 129. Few infections occurred in
persons of South or South East Asian origin (83 or 4%;
mainly from Afghanistan (14), India (18), and Indonesia
(19)), and in persons of Middle or South American ori-
gin (58 or 3%; mainly Surinam (42)). Infections in all
these groups decreased.
Number of travellers and the use of malaria
chemoprophylaxis
The number of travellers visiting the malaria-endemic
regions for which the LCR recommends malaria chemo-
prophylaxis increased from 247,000 in 2000 to 384,000
in 2007 [12]. The number of travellers to the Middle
and West African sub-region almost doubled over time
from 16,000 to 31,000, but the proportion of travel to
this region is rather small (range 3-13%) compared to
other the regions.
In the same period, the number of prescriptions for
malaria chemoprophylaxis issued by Dutch pharmacies
rose steadily by 42%, from 131,400 in 2000 to 186,300
in 2007. In 2000, the combination drug atovaquone/
proguanil was registered for the use of malaria chemo-
prophylaxis, whereupon it gradually replaced the num-
ber of prescriptions for mefloquine and proguanil. In
2007, 76% of all prescriptions were atovaquone/pro-
guanil. Figure 2 shows the proportional change in the
use of malaria chemoprophylaxis and the absolute
growth of the number of travellers to malaria-endemic
countries. Despite the increased number of prescrip-
tions for malaria chemoprophylaxis, the proportion of
protected travellers decreased from 53% (115,600) of
all travellers in 2000 to 48% (197,700) of all travellers
in 2007.
Trends in incidence of imported Plasmodium falciparum
malaria
Figure 3 shows the estimated annual incidence of P. fal-
ciparum malaria imported in unprotected travellers and
in all travellers from the Netherlands, combined with
the number of travellers. The estimated incidence was
highest in 2002 (27.5/10,000 unprotected travellers) but
dropped from 21.5 in 2000 to 6.6 infections per 10,000
unprotected travellers in 2007 (p < 0.001). The inci-
dence in all travellers (i.e., protected and unprotected)
declined from 10.0 to 3.4 infections per 10,000 travellers
(p < 0.001). This drop is for the most part caused by the
decreased importation from Africa, in particular from
Middle and West Africa (from 121.3/10,000 travellers in
2000 to 36.5/10,000 travellers in 2007, p < 0.001). Fig-
ures 4, 5 and 6 show the incidence changes per region
and sub-region. Except for Asia (p = 0.15) and Middle
America (p = 0.5), all areas showed significant declining
trends (p < 0.001, except South East Asia, p = 0.03),
however the number of infections were small for these
regions.
Discussion
The results of this study show a steep and declining
trend in malaria infections since 2000. This is in striking
contrast to the steady increase in imported cases that
began in the 1970s [15]. Despite increasing travel to
malaria-endemic countries, the estimated incidence of
imported P. falciparum infections per 10,000 travellers
declined from 10.0 in 2000 to 3.4 in 2007. This decrease
is not readily explained by an increased uptake of
malaria chemoprophylaxis, because the observed
increase of prescriptions for chemoprophylaxis did not
match the growth in travel. Moreover, despite the addi-
tional number of travellers at risk, the estimated inci-
dence of imported P. falciparum fell from 21.5 to 6.6
infections per 10,000 unprotected travellers.
In this study, incidence estimates were calculated
assuming that P. falciparum infection occurs only in tra-
vellers not using malaria chemoprophylaxis. Other stu-
dies confirm this [16-19], and several surveys show that
up to 60% of travellers are not protected against malaria
[20,21]. Of course it is likely that some of the imported
infections in the Netherlands were caused by incorrect
use of malaria chemoprophylaxis, rather than non-use.
Improved drug compliance over time may have contrib-
uted to the observed decrease of imported malaria. It is
likely that the increased use of atovaquone/proguanil,
since 2000, has enhanced compliance with chemopro-
phylaxis [22,23], and in this way contributed to the
decreased importation of malaria. Yet, some studies
f o u n dn od i f f e r e n c ei nc o m p l i a n c ea m o n gt h ev a r i o u s
prophylactic regimens [24-26]. Furthermore, how
patients comply depends on many more variables than
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Page 5 of 10Figure 2 Number of collected prescriptions for malaria chemoprophylaxis (shown in bars), and total number of travellers to malaria-
endemic regions (shown in line), the Netherlands, 2000-2007.
Figure 3 Overall incidence of imported Plasmodium falciparum malaria in the Netherlands, 2000-2007, and number of travellers to
malaria endemic regions.
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Page 6 of 10Figure 4 Region-specific of imported Plasmodium falciparum malaria in the Netherlands, 2000-2007, and number of travellers to
malaria endemic regions - Africa.
Figure 5 Region-specific of imported Plasmodium falciparum malaria in the Netherlands, 2000-2007, and number of travellers to
malaria endemic regions - Central and South America.
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Page 7 of 10the chemoprophylactic drug itself, such as personal
characteristics, perception of risk, and travel destination
[27-29]. The risk of infection in travellers not using
malaria chemoprophylaxis depends on other factors too.
For example, the use of personal protective measures,
such as impregnated bed nets and mosquito repellents,
reduces the risk of infection considerably. Lastly, the
risk of infection depends on the malaria endemicity,
which varies per country, within a country or region,
but also may depend on the season of travel. In some
travel destination personal protective measures offer suf-
ficient protection against infection. In conclusion, this
may have led to an underestimation of the true inci-
dence, but still allowed us to analyse the declining
trends.
The drop in incidence of imported P. falciparum
infections is greatest in travellers returning from Middle
and West Africa, even though travel to this sub-region
has doubled. Other studies likewise describe a declining
incidence of malaria imported from West Africa
[4,18,30]. Most malaria infections in the Netherlands are
acquired in that region, and occurred in immigrants,
m a i n l yV F Rf r o mG h a n aa n dN igeria. The importation
of malaria by VFR from this region decreased from 138
infections in 2000 to 69 infections in 2007, making a
large contribution to the observed decline in incidence.
Also among tourist travellers, the number of infections
from this region (mainly from Ghana and the Gambia)
decreased from 65 infections in 2000 to 25 infections in
2007.
An explanation may be a decreased risk of infection in
their destination country [30]. Indeed, in some African
countries a reduction in local malaria transmission is
reported, especially in urban areas [31]. Some countries
have achieved a high coverage of measures to control
malaria, including extended use of bed nets treated with
insecticide and improved access to malaria treatment,
resulting in a large fall in the number of malaria cases
and deaths between 2000 and 2007 [2,32]. At the same
time in some other countries like Ghana and Nigeria,
there was no evidence of a true reduction in malaria
infections, and most parts of Africa are still considered
areas of high endemicity [2,33]. Yet VFR may have
improved their accommodations when visiting, e.g. by
investing in better local housing, often in cities and
urban areas, and having better access to protective
Figure 6 Region-specific of imported Plasmodium falciparum malaria in the Netherlands, 2000-2007, and number of travellers to
malaria endemic regions - Asia.
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treated bed nets. In 2001, the public health service of
Amsterdam studied factors determining the use of pre-
travel preventive services by VFR traveling to West
Africa from the Netherlands. The researchers concluded
that some West Africans (in particular, non-Ghanaians,
illegal immigrants, and immigrants leaving at short
notice) were not consulting pre-travel preventive health
services [34]. An explanation for the observed decrease
in malaria imported by Ghanaian VFR may be that their
uptake of malaria chemoprophylaxis has improved even
more than in other groups.
A limitation of this study may be that the travellers
statistics, based on the Continuous Holiday Survey, did
not include non-Dutch and illegal immigrants. In the
Netherlands, a large proportion (50%) of the resident
West Africans have no legal status, although this per-
centage is less among people from Ghana than those
from Nigeria [34]. (Illegal) immigrants were classified in
the VFR category, but were not represented in the
denominator. Any resulting overestimation of the inci-
dence of malaria in West African travellers would be
small, as illegal immigrants lack official documents per-
mitting regular travel.
Another limitation of this study is that for some conti-
nental regions, country-specific travellers statistics were
unavailable. In estimating the incidence specific to
regions and sub-regions, only travellers statistics of
countries for which the Malaria Working Group of the
Dutch LCR advises malaria chemoprophylaxis were
used. This produced however some denominator pro-
blems. For South America data for the whole sub-region
were used as travel data to malaria-endemic and
non-endemic countries could not be separated,. As
mentioned previously this may have led to an underesti-
mation of the true incidence of infection from the indi-
vidual malaria-endemic countries.
Conclusion
The declining incidence of imported malaria is not
easily explained and likely to be multi-factorial. The
decline is positive, but the increasing number of travel-
lers from the Netherlands using no malaria chemopro-
phylaxis remains a concern. Despite the current
optimism about decreasing malaria transmission in sev-
eral parts of the world, vigilance is needed for the grow-
ing lack of awareness among travellers and, therefore,
the growing need for prophylactic measures. In 2008, a
cluster of 56 European tourist travellers returned from
Gambia with P. falciparum,o fw h i c ht h r e ed i e d .A l l
patients did not use, or wrongly used chemoprophylaxis
[35]. For some malarious destinations, such as the
Indian subcontinent and Middle and South America,
less strict guidelines on malaria prophylaxis seem plausi-
ble [36,37]. However, an improved effort is needed to
increase awareness and protection among the growing
number of travellers to Africa and other areas endemic
for P. falciparum.
Additional material
Additional file 1: Travel destinations used for travellers statistics.
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